ABBV vs TTD: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and The Trade Desk, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-16.
AbbVie Inc. · Healthcare
$208.05
+4.5% upside to fair value
Grade C
High Quality
VS
The Trade Desk, Inc. · Technology
$22.76
+488.8% upside to fair value
High Conviction
Grade A-
QuantHub Verdict
TTD has more upside to fair value
(+488.8%).
ABBV trades at a lower forward P/E
(14.9x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
TTD |
| Current Price |
$208.05 |
$22.76 |
| Fair Value Estimate |
$217.50 |
$134.00 |
| Upside to Fair Value |
+4.5%
|
+488.8%
|
| Market Cap |
$367.9B |
$10.8B |
| Forward P/E |
14.9x
|
24.6x
|
| EV / EBITDA |
16.7x
|
—
|
| Price / Sales |
6.1x
|
3.7x
|
| Price / FCF |
20.9x
|
13.8x
|
| Revenue Growth YoY |
+8.6%
|
+14.5%
|
| Gross Margin |
83.7%
|
78.6%
|
| Operating Margin |
34.7%
|
20.3%
|
| Return on Equity |
-129.24%
|
16.9%
|
| Dividend Yield |
3.2% |
— |
| FCF Yield |
4.78%
|
7.3%
|
| Analyst Consensus |
Buy
|
Buy
|
Investment Thesis
AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience. Full-year 2025 revenue reached $61.2 billion with a gross margin of 83.7% and operating margin of 34.7%, demonstrating operational strength despite the ongoing Humira erosion. Management guides to $67 billi…
The Trade Desk is the largest independent demand-side platform for programmatic advertising with 78.6% gross margins. After recent sell-off, stock trades at 3.2x forward P/S vs historical higher multiples, offering upside if growth stabilizes at 15%+. A-tier business at cheap valuation.[1]
Accumulation Zones
| Metric |
ABBV |
TTD |
| Zone Low |
$163.13 |
$100.00 |
| Zone High |
$184.88 |
$114.00 |
| In Buy Zone? |
No
|
Yes
|